Multiple Sclerosis in 2022

Introduction and Background

Dr. Krieger's background, experience, and contributions in the field of neurology.

Dr. Krieger's Professional Journey

• Dr. Krieger received his MP3 from the university, completed residency at Mount Sinai, and fellowship at the Corinne Goldsmith Dickinson Center for Multiple Sclerosis.

• He served as a neurology residency program director for 10 years and maintains a clinical practice at the CGD Center for MS.

• Dr. Krieger has been involved in numerous MS clinical trials and is known for proposing the topographical model of MS.

Clinical Course of Multiple Sclerosis

An overview of multiple sclerosis focusing on its clinical manifestations and diagnostic challenges.

Clinical Presentation of MS

• MS is an inflammatory and autoimmune disease solely affecting the central nervous system.

• Characterized by relapses of neurological symptoms followed by functional impairment progression.

• Symptoms can vary widely among individuals, including weakness, numbness, vision issues, and imbalance.

Diagnostic Criteria and MRI Findings

Discussion on recognizing MS through clinical course evaluation and characteristic MRI findings.

Diagnostic Criteria and Imaging

• Importance of recognizing characteristic MRI findings specific to MS to differentiate it from other conditions.

• Highlighting the variability in early symptoms leading to challenges in diagnosis initially.

• MRI plays a crucial role in detecting lesions indicative of MS that aid in diagnosis confirmation.

MS Relapse Characteristics

Exploring the nature of relapses in multiple sclerosis patients.

Understanding Relapses

• Relapses or attacks in MS typically emerge over days to weeks mirroring inflammation patterns.

• Symptoms evolve gradually during an attack before receding.

Multiple Sclerosis: Clinical Overview

In this section, the speaker discusses multiple sclerosis (MS) relapses, symptoms, and their impact on different parts of the body.

MS Relapses and Symptoms

• MS relapses are inflammatory phenomena rather than brief electrical events. They manifest as optic neuritis affecting the optic nerve, brain stem dysfunction leading to double vision and vertigo, cerebellar dysfunction causing ataxia and imbalance, and spinal cord symptoms like hemisensory loss or weakness in both legs.

• Diagnosing MS involves distinguishing it from other conditions by localizing symptoms to central nervous system damage. Symptoms are not vague but focal lesions causing specific findings.

• Charcot's triad for MS includes intention tremor, nystagmus, and scanning speech, indicating cerebellar involvement due to white matter pathway vulnerability to demyelination.

Epidemiology of Multiple Sclerosis

This part delves into the demographics of individuals affected by MS and its prevalence in different populations.

Demographics and Prevalence

• MS primarily affects young adults aged 20 to 40 but can also occur in pediatric cases up to geriatric patients. Women are more commonly affected than men at a ratio of two to three to one.

• In the U.S., approximately one million people have MS, making it the most common cause of acquired disability in young adults. Historically associated with northern European descent, modern recognition acknowledges its impact across all backgrounds.

Clinical Phenotypes of Multiple Sclerosis

The discussion focuses on the clinical phenotypes of MS - relapsing-remitting, secondary progressive, and primary progressive - as defined by Fred Loveland.

Clinical Phenotypes

• The classification of MS into relapsing-remitting, secondary progressive, or primary progressive types aids in treatment decisions based on distinct clinical patterns observed in patients.

• Unlike diseases with varied biological mechanisms for each phenotype, these classifications describe how patients present clinically rather than reflecting diverse underlying processes.

Clinical Presentation and Diagnosis of Multiple Sclerosis

In this section, the speaker delves into the clinical presentation and diagnosis of multiple sclerosis (MS), highlighting key phases and diagnostic criteria.

Understanding MS Phases

• The clinical picture of MS involves relapses of disability and recovery over time, with phases including subclinical, initial demyelinating event, relapsing-remitting MS, and secondary progressive MS.

• MRI scans play a crucial role in detecting new lesions below the surface, emphasizing the importance of monitoring disease activity beyond visible relapses.

Outdated Statistics and Harmful Misconceptions

• Historical statistics indicating a 50% chance of progression in 10 years for MS patients are outdated and misleading in the modern era.

• The persistence of such statistics on the internet can instill unnecessary fear in patients, hindering their understanding of current treatment capabilities.

Clinical Picture and Optic Neuritis

• Optic neuritis is a common initial attack in MS characterized by inflammatory optic nerve lesions leading to vision loss.

• Symptoms include pain in the eye, visual blurring, central vision loss, desaturated color vision, scotoma, reflecting specific patterns indicative of optic neuritis.

Diagnosing Multiple Sclerosis: McDonald Criteria

This segment focuses on diagnosing MS using the McDonald Criteria based on lesion dissemination in space and time.

McDonald Criteria Simplified

• The McDonald Criteria emphasize lesion dissemination in space (multiple CNS lesions) and time (progression over time), essential for diagnosing MS accurately.

• Classic lesions meeting specific criteria serve as key indicators for confirming dissemination in space within the nervous system during diagnosis.

Any Two Any New Criteria

• The "Any Two Any New" criteria streamline the diagnostic process by requiring two classic lesions initially for spatial confirmation and any new lesion over time for temporal confirmation.

Identifying Classic Lesions on MRI Scans

Exploring classic lesions on MRI scans aids in identifying specific patterns indicative of multiple sclerosis.

Types of Classic Lesions

• Juxtacortical lesions located under the cortex, periventricular lesions touching ventricles, and posterior fossa lesions impacting cerebellar white matter are distinctive markers seen on MRI scans.

• Understanding these lesion types helps clinicians recognize characteristic damage patterns associated with different areas of the brain affected by MS.

Detailed Analysis of Multiple Sclerosis Lesions

In this section, the speaker discusses various aspects of multiple sclerosis lesions seen in MRI scans, highlighting their characteristics and locations.

Characteristics of MS Lesions

• Lesions are oval-shaped and ovoid, resembling spokes radiating outwards like Dawson's fingers. This shape is a common feature in MS literature.

• On sagittal view, lesions point upwards from the corpus callosum at a right angle to the ventricle, indicating involvement of the inferior surface of the corpus callosum. This pattern is considered classic for MS.

Examples of Lesions in Different Areas

• Posterior fossa lesions causing symptoms like intention tremor are visible in the pons and middle cerebellar peduncle on an MRI scan. These areas show demyelinated lesions that were previously only observable post-mortem.

• With contrast gadolinium, MS lesions can often enhance with a ring-like appearance. Periventricular ovoid lesions, infertentorial regions, cerebellar peduncles, and juxta-cortical ones are common presentations. Spinal cord lesions are crucial for prognosis as they directly cause symptoms like optic neuritis.

Importance of Spinal Cord Lesions

• Spinal cord lesions play a significant role in MS prognosis as they lead to symptoms such as optic neuritis visible on MRI scans through enhancement in the optic nerve region. The optic nerve is essentially an extension of the brain reaching out to the eye and is myelinated similarly to brain tissue.

Impact of Brain Atrophy in Multiple Sclerosis

This segment delves into how multiple sclerosis affects not just lesion formation but also leads to overall brain shrinkage or atrophy over time.

Brain Shrinkage in MS

Diagnosis of Multiple Sclerosis

In this section, the speaker discusses the challenges and considerations in diagnosing multiple sclerosis (MS), emphasizing the importance of differential diagnosis and ruling out other conditions that can mimic MS symptoms.

Differential Diagnosis Criteria

• The diagnostic criteria for MS require ruling out other potential explanations for symptoms, which spans various medical and infectious diseases.

Psychogenic Symptoms

• Psychogenic symptoms, such as depression, somatic features, tingling, and numbness, can mimic MS. These patients often undergo MS workups due to non-specific symptoms.

Importance of Accurate Diagnosis

• Early diagnosis of MS is crucial for effective treatment but comes with the risk of misdiagnosis. Research by Andy Solomon highlights the challenges in differentiating MS from other conditions.

Misdiagnosis in Multiple Sclerosis

This section delves into a study on misdiagnosed cases of MS, exploring alternative diagnoses and highlighting the need for specificity in neurological assessments.

Study on Misdiagnosis

• A study examined 110 individuals misdiagnosed with MS due to atypical symptoms and lack of objective evidence. Alternative diagnoses included migraine, fibromyalgia, conversion disorder, or inflammatory diseases.

Imaging Red Flags

• MRI scans can reveal red flags indicating conditions other than MS. For instance, peripherally situated dots in white matter suggest migraine rather than typical MS lesions.

Lesion Localization in Multiple Sclerosis

This part focuses on the significance of lesion localization in diagnosing multiple sclerosis and explains how specific immunological processes contribute to demyelination.

Lesion Localization Importance

• Lesions' distribution around veins draining blood from the brain (perivenular) is a hallmark feature of multiple sclerosis due to its specific immunology.

Immunological Process

• CD4 positive T cells are activated against myelin antigen outside the central nervous system before gaining access through compromised blood-brain barrier. Once inside, they cause demyelination by attacking myelin.

Lesion Localization in Multiple Sclerosis

In this section, the speaker discusses lesion localization in multiple sclerosis (MS) and its connection to the inflammatory response in the central nervous system.

Lesion Localization and Inflammatory Response

• Lesions in MS are found in areas with permeable bloodstream, particularly perivenular areas. This localization is crucial for understanding the disease.

• Oligoclonal bands detected through a spinal tap are indicative of an inflammatory response in the central nervous system, a classic test for MS diagnosis.

• Recent research suggests Epstein-Barr virus may trigger MS by making the immune system self-reactive, shedding light on potential causes of the disease.

Disease Topography: Understanding Lesion Distribution

The speaker delves into disease topography, emphasizing lesion distribution across different regions of the central nervous system and its impact on symptoms.

Disease Topography and Symptom Manifestation

• Disease topography focuses on lesion distribution in various CNS regions like spinal cord, optic nerve, brain stem, cerebellum, and periventricular areas.

• Periventricular lesions are often well compensated compared to lesions in other regions that cause noticeable symptoms due to varying levels of reserve capacity within different CNS areas.

Clinical Course of Multiple Sclerosis

The speaker illustrates how lesions progress over time in MS patients, leading to distinct clinical manifestations based on lesion location and reserve capacity.

Progression of MS Lesions

• Initial lesions may not cause visible symptoms if they remain below a certain threshold of reserve capacity; however, as new lesions form over time, symptomatology can vary based on lesion location.

• As disease progresses, brain atrophy signifies a decline in reserve capacity leading to unmasking of symptoms associated with deeper brain lesions such as those affecting balance or speech—a hallmark of progressive MS.

Treatment Approaches for Multiple Sclerosis

The speaker outlines treatment strategies for managing relapses, modifying disease progression, addressing symptoms effectively while highlighting the importance of comprehensive care.

Managing MS: Treatment Strategies

Treatment Strategies for Multiple Sclerosis

In this section, the speaker discusses the treatment approach for multiple sclerosis (MS), emphasizing the distinction between relapse and other conditions that may mimic it.

Distinguishing Relapse from Other Conditions

• High-dose steroids like methylprednisolone are used to treat true new lesions in MS, not just symptom recurrence.

• Differentiating a relapse from overheating-induced symptoms is crucial; overheating can unmask underlying deficits but is not a true new event.

Considerations in Treatment Selection

• Caution is advised when administering high-dose steroids; differential diagnosis should include urinary tract infections, COVID fever, and dehydration.

• Disease-modifying therapies in MS vary in administration methods, safety profiles, and efficacy levels.

Current Landscape of MS Treatment Options

This part delves into the diversity of disease-modifying therapies available for MS treatment and the considerations involved in selecting an appropriate medication based on individual patient characteristics.

Diversity of Medications

• Tailoring treatment involves prioritizing highly effective medications for severe cases with extensive lesions while opting for safer options for patients with mild disease.

• Patients with comorbidities may require adjustments in medication selection to prioritize safety over efficacy.

Challenges in Personalizing Treatment

• Lack of genetic predictors or molecular assays hinders personalized medicine selection; decisions are currently based on soft biomarkers and clinical judgment.

• Frequency of dosing, patient preferences, and lifestyle factors influence medication choice despite limited predictive biomarkers.

Future Directions and Challenges in MS Treatment

The speaker reflects on the evolving landscape of MS treatment strategies, highlighting the need for advancements such as predictive biomarkers to enhance personalized medicine approaches.

Evolving Treatment Paradigms

• Comparison drawn between neurology's approach to MS treatment and oncology's use of molecular diagnostics; emphasizes the potential future role of genetics in refining treatment decisions.

Symptom Management and COVID-19 Impact

The speaker discusses managing symptoms in patients with MS, navigating the impact of COVID-19 on individuals with MS, and the vulnerability of patients to severe outcomes during the pandemic.

Symptom Management

• Patients with MS were not inherently more vulnerable to severe COVID-19 outcomes unless they had progressive MS.

• Individuals with advanced comorbidities and disabilities faced higher risks of hospitalization and death during the pandemic.

COVID-19 Impact

• B-cell depleting monoclonal antibodies like ocrelizumab increased COVID morbidity slightly, emphasizing safety measures over stopping treatments.

• Encouragement for all patients on disease-modifying therapies to get vaccinated against COVID-19 for protection.

MS Center at Mount Sinai Overview

Insight into the comprehensive care provided at the MS center, including various specialists involved in patient care and advancements in treatment outlook for individuals diagnosed with MS.

Center Overview

• The center offers cutting-edge care along with comprehensive chronic disease management for individuals with MS.

Treatment Outlook

• Optimistic outlook on treating MS faster than disease progression through advancements in treatment methods.

New Section

In this section, the speaker discusses challenges faced in delivering re-myelinating agents to the central nervous system due to the blood-brain barrier's limitations.

Challenges in Drug Delivery

• Re-myelinating agents like opicinomab stimulate oligodendrocyte precursor cells but fail in patients as monoclonal antibodies are too large to cross the blood-brain barrier effectively.

• Strategies for remyelination and stem cell therapies face similar challenges in accessing the central nervous system efficiently.

New Section

The speaker delves into the complexities of combining therapies in multiple sclerosis treatment and highlights past unsuccessful combination studies.

Combination Therapy Challenges

• Multiple sclerosis treatments primarily rely on monotherapy due to risks associated with combination immune suppression observed in earlier trials.

• Past combination studies involving old-school medicines did not show improved efficacy compared to individual treatments, leading to cautiousness towards further combination trials.

New Section

The discussion shifts towards the potential of future combination therapies alongside remyelination and neural repair strategies.

Future Prospects

• Despite setbacks from previous combination trials causing issues like PML, there is optimism for future combinations with emerging remyelination and neural repair therapies.

• Combining immune process shutdown with repair strategies could be a promising approach for multiple sclerosis treatment advancements.

New Section

The conversation touches upon how immune checkpoint inhibitors may impact inflammatory demyelinating processes and their relation to multiple sclerosis.

Immune Checkpoint Inhibitors

• Checkpoint inhibitors can unmask inflammatory demyelinating processes, potentially different from multiple sclerosis, triggering debates within the field.

• Similarities exist between checkpoint inhibitors and TNF alpha inhibitors in unmasking inflammatory demyelinating diseases, emphasizing caution when modulating the immune system.

Diagnosis of Multiple Sclerosis

The discussion revolves around the diagnosis of multiple sclerosis (MS) and the criteria for confirming an MS diagnosis based on specific events and lesions.

Confirming MS Diagnosis

• It is relatively easy to confirm an MS diagnosis nowadays if a person has experienced one definitive event and has two lesions in appropriate locations.

Treatment Consideration

• Patients who have had a definitive event and show MRI scans indicative of MS may benefit from treatment for the disease.

Support for Patients